Azra Ai

Azra AI (operating under owner entity Invenero Health LLC) is a Franklin, Tennessee-based healthcare technology company that applies natural language processing and AI to unstructured clinical data in order to identify patients who need cancer treatment or follow-up care and to automate the surrounding workflows. Its platform interprets pathology, radiology and other clinical documentation to flag suspected cancer cases and incidental findings such as lung nodules, then drives downstream engagement, scheduling and care coordination.

The company describes an end-to-end platform spanning incidental findings (radiology), cancer patient identification (pathology), patient navigation and care coordination, cancer registry case-finding and abstraction, multidisciplinary meeting/tumor board support, clinical trial matching, ED discharge, and real-time reporting and analytics. A component described as the Clinical Patient Data Layer converts fragmented clinical data into structured, actionable workflows across radiology, pathology, cardiology and emergency departments. Alongside software, Azra offers hands-on clinical services including navigation, case finding, tumor board coordination and program execution.

The technology lineage traces to Digital Reasoning, whose original AI models for unstructured data were used by U.S. national intelligence organizations after 9/11 and later in law-enforcement applications before being applied to healthcare. Azra AI was formed in January 2022 around those healthcare assets.

Founding story

Chris Cashwell founded Azra AI in January 2022, building it around the healthcare assets of the company formerly known as Digital Reasoning. Cashwell had led the healthcare workflow automation and AI unit of Digital Reasoning Systems, which was acquired by Smarsh in 2020, and previously served as General Manager and SVP of Digital Reasoning Health. In late 2021 he told Smarsh management — whose core focus was the financial sector — that he wanted to pursue the healthcare line, and received approval to set a divestiture in motion. Cashwell initiated and led the transaction himself, without an auction or investment banker, and lined up investors selectively. Earlier in his career he was CEO of Lincor Solutions, head of emerging technologies at Nuance Healthcare, and a leader in GE Capital and GE Commercial Finance.

Business model

Azra AI sells an enterprise software platform to hospitals and health systems, complemented by clinical services such as patient navigation, registry case finding, tumor board coordination and strategic program execution. Deployments sit alongside EHRs, addressing specialized clinical workflows the company says EHRs and point solutions were not designed for.

Traction

At launch in March 2022, Azra reported a presence in more than 200 hospitals and 75 cancer centers, with customer sites concentrated in the HCA Healthcare and Inspira Health networks, and processing data from millions of unstructured clinical records per month. A March 2022 release stated the technology decreased time from diagnosis to treatment by seven days across all cancer types, improved patient retention by 75 percent and increased adopting providers' revenues by over 10 percent in the first 14 months of use. By April 2026 the combined Azra AI and Thynk Health platforms were deployed across hundreds of hospitals, including five of the top ten U.S. health systems, processing well over half a billion clinical reports and messages annually.

Latest developments

In April 2026 Azra AI announced the acquisition of Thynk Health, a specialist in lung cancer screening and incidental findings management, on undisclosed financial terms. John Marshall continues as CEO of the combined organization, while Thynk's CEO Daniel Weeks became Chief Operating Officer. Both companies said existing customer deployments would continue without disruption during integration, and Thynk customers gain access to Azra's full platform.